Publicly-traded company Aquestive Therapeutics Inc. (NASDAQ:AQST) had a closing price of $5.23 yesterday. Meanwhile, the average 12-month price target from Wall Street analysts is currently $18.00, this means that the stock is underpriced by 70.94%. In the past 52 weeks the company’s stock price has moved within the range of $2.95 to $18.49.
This particular stock’s 5-day moving average is 4.33, its 20-day moving average is 3.65 and its 100-day moving average is 3.74. Aquestive Therapeutics Inc. (AQST) currently has 23.52M shares outstanding, which means that its market capitalization is $123.01M.
The Details: Aquestive Therapeutics Inc. (AQST) Financial Health
It’s also useful to check out a company’s operating margin, which lets us know how much profit is retained after taking operating costs and depreciation into consideration. Aquestive Therapeutics Inc. (AQST) has an operating margin of -99.10%.
We can also look at Return on Assets, which is a percentage that tells us how good a public company is at using its current assets to generate a profit. Higher percentages mean that the company is better at using its assets. At the moment, Aquestive Therapeutics Inc. Return on Assets is -87.00%.
What Does Wall Street Say about Company?
When selecting stocks to purchase, many investors want to know what Wall Street analysts are thinking before they pull the trigger. They often look for the average analyst rating. At the moment, the average analyst rating for AQST is Buy. Out of 6 total analysts who were surveyed, 0 rated it a sell, 0 rated it a underweight, 0 rated it an overweight, 0 rated it hold, and 6 rated it a Buy.
Three months ago, on the other hand, the average analyst rating for Aquestive Therapeutics Inc. (AQST) was a Buy – from a survey of 5 analysts. Of the analysts who provided ratings, 0 rated the company a Hold, 0 rated it a Sell, 0 rated it an overweight, 0 rated it an underweight, and 5 rated it a Buy.
Understanding Profitability at Aquestive Therapeutics Inc. (AQST)
A good method of evaluating a public company’s profitability is by taking a look at its Earnings per Share (EPS) performance. In the most recent financial results released by Aquestive Therapeutics Inc., for the quarter ending on 12/2019, the company posted EPS of -0.80. The average estimate of Wall Street analysts had projected -0.76.
Wall Street analysts, on average, are forecasting the company’s EPS to be -0.69, compared to -0.56 reported in the same quarter last year. When it comes to net revenue, the average estimate from a total of 6 analysts is 9.65M – compared to 16.82M posted in the year-ago period.